Replicel Life Sciences Inc. · OTC:REPCF
Replicel Life Sciences — Investor Presentation (2021)
46 slides from Replicel Life Sciences's investor presentation, 2021
Slide 1: Today's Innovation. Tomorrow's Products.
Today’s Innovation. Tomorrow’s Products. Rejuvenation | Regeneration | Regrowth
Slide 2: Hair regrowth. Skin rejuvenation. Tendon regeneration.
3 Hair regrowth. Skin rejuvenation. Tendon regeneration. Innovative cell therapies. Unparalleled dermal injection technology. A revolution in sports medicine and aesthetics
Slide 3: Today's Innovation. Tomorrow's Products
Today’s Innovation. Tomorrow’s Products
Slide 4: RepliCel Financial
TSV: RP | OTCPK: REPCF | FRA: P6P2 (as of 10 Feb 2021) ($CAD) Current market cap: ~$14M Total capital raised by private placement: ~$34M (+ 3.5M pending to MainPointe) Total transactional revenue to-date: ~$4M (upfront licensing payments from Shiseido) ~$5M (upfront licensing payment & investment fr
Slide 5: RepliCel Ownership
TSV: RP | OTCPK: REPCF | FRA: P6P2 (as of 10 Feb 2021) ($CAD) Management Ownership: ~6.4M (~17%) Strategic Partnership Ownership ~$9.4M (25%) YOFOTO: 5.3M @ $0.95 / share (2018) MainPointe: 4.0M @ $0.675 / share (2021) RepliCel Retail investor base (Canadian, US, European) ~21.2M (~58%) Ownership *
Slide 6: RepliCel Strategic Partnerships
RepliCel Strategic Partnerships Greater China ∙ RCT-01 Tendon ∙ RCS-01 Skin ∙ RCI-02 Dermal Injector ∙ Exclusive 10-year license USA ∙ RCI Dermal Injector ∙ 5-yr exclusive distributorship Asia ∙ RCH-01 Hair ∙ Exclusive permanent license ∙ Royalties for 10-yrs post launch in each country
Slide 7: 1 company. 2 clinical segments. 3 technologies. 4 products.
1.2.3.4 SPORTS MEDICINE AESTHETICS 1 company. Two cell therapies One medical device 2 clinical segments. 3 technologies. NBDSCs 4 products. DSCCs
Slide 8: Two Clinical Segments
1.2.3.4. Two Clinical Segments
Slide 9: Orthopedics. Aesthetics
Orthopedics. Aesthetics It is estimated Total Available Market: one in three people in industrialized nations One in three people are affected by conditions RepliCel is targeting: Aging and sun-damaged skin Hair loss Chronic tendon degeneration..
Slide 10: Achilles Tendon – Market Metrics
Achilles Tendon – Market Metrics 11 656,211 232,000 Estimated annual number of Achilles tendon sports Annual incidence rate of mid-portion Achilles injuries in the US (2002)2 tendinopathy in North America alone1 5-9% of recreational runners develop Achilles tendinopathy3 4% of all patients seen in s
Slide 11: Market Metrics - Global Aesthetics Market
Market Metrics - Global Aesthetics Market (RCS-01 & RCI-02) 2013 statistics from American Society of Plastic Surgeons and GBI Research 6.7M injections up 6% YOY Botulinum Toxin 2.3M procedures up 3% YOY Soft Tissue Fillers $2.5 Billion 1.7M procedures spent on facial Hyaluronic up 18% YOY aesthetics
Slide 12: Hair Loss – Market Metrics
Hair Loss – Market Metrics $3.5B spent on hair loss treatments $2.5 Billion spent on all surgical procedures 697,372 non-surgical patients 99% of all products being marketed are completely Hair Androgenetic Alopecia ineffective.* restoration 358,109 surgical patients affects an estimated Patients 50
Slide 13: Three Technologies
1.2.3.4. Three Technologies
Slide 14: NBDS Technology
NBDS Technology NBDS cells RCT-01 Tendon Regeneration The NBDS RCS-01 Skin Rejuvenation technology treats two indications both caused by Non-bulbar dermal sheath (NBDS) cells are prolific collagen producers of tissue building proteins especially type I deficiencies – skin collagen (5x that of dermal
Slide 15: DSC Technology
DSC Technology DSC cells RCH-01 Hair Regrowth The DSC The dermal sheath cup (DSC) cells manufactured by technology treats RepliCel are resistant to the effects of androgenetic alopecia. hair loss caused DSC cells have been shown to engraft and regrow hair by a deficit of fibers in follicles which ha
Slide 16: RepliCel's Innovative Cell Manufacturing
RepliCel’s Innovative Cell Manufacturing 5
Slide 17: Ensuring controlled delivery
Ensuring controlled delivery • More consistent dermal injections; more consistent outcomes • Less local anesthetic; better patient experience • Shorter procedure time • Increased control over injection depth, dose, and dispersion
Slide 18: Four Products
@> ~» y | we Ve . \ WV =. Using Cells for Healing 1.2.3.4. Four Products
Slide 19: Today's Innovation. Tomorrow's Products.
Today’s Innovation. Tomorrow’s Products. Chronic Tendinopathy Androgenetic Alopecia Improved delivery of cells, (Achilles Tendon, Golfer’s Elbow, Aging and Sun-Damaged Skin toxins, fillers, fat transfers, Tennis Elbow, Jumper’s Knee, (male and female pattern hair steroids, drugs, genes, biologics, R
Slide 20: RCT-01 Tendon Regeneration
0 Replicel” Using Cells for Healing RCT-01 Tendon Regeneration
Slide 21: 9
9
Slide 22: Tendinopathy - Numerous Applications
Tendinopathy - Numerous Applications 15 Rotator Cuff Tennis Golfer’s Elbow Strong safety profile and indicative Elbow efficacy data suggests a potential Gluteus Medius for RepliCel’s RCT-01 therapy to treat multiple types of tendon Patellar “Jumper’s degeneration, clinically diagnosed Knee” as “tend
Slide 23: RCT-01 Tendon Regeneration. Clinical Data
RCT-01 Tendon Regeneration. Clinical Data PHASE 1/2a CLINICAL TRIAL Final Results: Trial met its goal to prove safety. No serious adverse events. Most clinically material improvements seen 6 months after receipt of Randomized (3:1) double-blind, injections include: placebo-controlled trial at UBC Sp
Slide 24: Sample Tendon Regeneration
Sample Tendon Regeneration Ultrasound Image of 65 Yr. Old Before Treatment – Day 1 Darkened areas show damaged tendon Sample Patient Image Demonstrating White areas Potential for Tendon show Ankle Regeneration bone Ultrasound Image of 65 Yr. Old After Treatment – 6 Months Long white striations show
Slide 25: RCT-01 Program Status and Plan
RCT-01 Program Status and Plan Completed: Successful randomized, double- 2021: Phase 2 clinical trial expected to commence in blind, placebo-controlled phase 1 clinical trial 2021 in Republic of China completed (Canada) with RepliCel’s Chinese partner (chronic Achilles tendinopathy) RCT-01 2021: Cli
Slide 26: RCS-01 Skin Rejuvenation
= > ay tee S.C a. ‘ eal 4 f rerang .- RCS-01 Skin Rejuvenation
Slide 27: RepliCel
3 ‘ RepliCel
Slide 28: Aging and Sun-Damaged Skin
Aging and Sun-Damaged Skin (fine wrinkles) 15 Strong safety profile and statistically significant post-injection in vivo biological data showing impact on established biomarkers highly correlated with collagen production, suggest potential for RepliCel’s RCS-01 to regenerate the extra- YOUNGER SKIN
Slide 29: Biology of Aging and UV-Damaged Skin
Biology of Aging and UV-Damaged Skin UV exposure appears to be responsible for 80% of visible facial aging signs* 35 YEARS 45 YEARS 55 YEARS 35 YEARS 45 YEARS 55 YEARS Hyaluronic Acid Collagen Elastin SKIN AGING AND COLLAGEN LEVELS *Source: Flament, F., Bazin, R., Laquieze, S., Rubert, V., Simonpiet
Slide 30: RCS-01 Dermal Rejuvenation. Clinical Data
RCS - 01 Dermal Rejuvenation. Clinical Data PHASE 1 CLINICAL TRIAL Results: Phase 1 randomized, double-blinded, placebo- • No serious adverse events at the interim point of the trial were controlled trial at IUF Leibniz-Institut für reported. umweltmedizinische Forschung (completed) (Germany) (17 Pa
Slide 31: RCS-01 Program Status and Plan
RCS-01 Program Status and Plan Completed: Successful randomized, double- 2021: Phase 2 clinical trial expected to commence blind, placebo-controlled phase 1 clinical trial in 1H 2021 in Republic of China completed (Germany). with RepliCel’s partner RCS-01 2021: Clinical research study under ASRM 202
Slide 32: RCH-01 Hair Regrowth
Your look. Your nealiD wil regrowing hair RCH-01 Hair Regrowth
Slide 33: RepliCel
® Replicel
Slide 34: Androgenetic Alopecia
Androgenetic Alopecia 15 The Hair Cycle: From growth phase to resting phase Cellular structure of a hair follicle bulb disaggregates during the regression Strong safety profile and to resting phase. efficacy data in two clinical studies suggest the potential for RepliCel’s RCH-01 cell therapy to res
Slide 35: RCH-01 Hair Regrowth. Clinical Data (Phase 1)
RCH-01 Hair Regrowth. Clinical Data PHASE 1 CLINICAL TRIAL Results: Randomized, double-blind, placebo- • First-in-human, five-year follow-up firmly establishes product safety controlled, phase 1 clinical trial of a • Efficacy data collected from all 19 patients over 24 months produced single injecti
Slide 36: RCH-01 Hair Regrowth. Clinical Data (Phase 2)
RCH-01 Hair Regrowth. Clinical Data PHASE 2 CLINICAL STUDY Design: Randomized, placebo-controlled, double-blinded, • Participants received single injections of 7.5 × 106, 1.5 × 106, or clinical study on the efficacy and safety of cultured 3.0 × 105 DSC cells or a placebo in four randomized separate
Slide 37: RCH-01 Hair Regrowth. Clinical Data (Phase 3)
RCH-01 Hair Regrowth. Clinical Data PHASE 3 CLINICAL STUDY Design: • Interventional, open label, uncontrolled, single-arm study studying Multicenter clinical study on the efficacy and effect of repeated injection treatments of DSC cells in male safety with extensive and repeated injections subjects
Slide 38: RCH-01 Program Status and Plan
RCH-01 Program Status and Plan Completed: Randomized, double-blind, 2023: Pivotal multicenter clinical study testing the placebo-controlled efficacy of “extensive and repeated” injections of RCH- phase 1 clinical trial 01 on male and female pattern hair loss. Completed: Randomized, placebo- funded b
Slide 39: Ensuring controlled delivery
Ensuring controlled delivery • More consistent dermal injections; more consistent outcomes • Less local anesthetic; better patient experience • Shorter procedure time • Increased control over injection depth, dose, and dispersion
Slide 40: Delivery matters
Delivery matters To control the outcome, control the delivery. Delivery of cells has been a highly under-valued aspect of the cell therapy product development continuum. injection (standard vs proprietary; system vs local) spray pill / capsule (encapsulated) cell-loaded matrix/scaffold eng
Slide 41: Patented Dermal Injection Device – A Catalyst for Innovation
Patented Dermal Injection Device – A Catalyst for Innovation The RCI-02 dermal injector is designed to deliver cells, dermal fillers, drugs and biologics • Digital controls program for depth, volume, rate Electronic activator of dispersion (improves over manual plunger) • Provides exact repeatable d
Slide 42: RCI-02 Dermal Injector and Consumables. Program Status and Plan
RCI-02 -Dermal Injector and Consumables. Program Status and Plan Completed: First functional prototypes built 2021 Q1: Commercial-grade prototypes manufactured and initially tested 2017 and optimized in first production run. through 2020. 2021 2H: FDA 510(k) expected 2021 Q4: First product launch in
Slide 43: Next Steps in Japan
Ww Next Steps in Japan Nes 4 7 5 as ] Sendai Niigata w Replicel Using Cells for Healing
Slide 44: Cell Therapies Positioned for Success in Japan
Cell Therapies Positioned for Success in Japan RepliCel’s products have already been the subject of 4 well-controlled, clinical studies involving 100+ patients Successful completion of first 2 PMDA consults Both cell therapies being prepared for ASRM clinical research & commercialization Jap
Slide 45: One Platform. Two innovative cell therapies.
Seeking co-development and commercialization partners in Japan One Platform. Two innovative cell therapies. RCT-01 Tendon regeneration ▪ Preparing to launch ASRM clinical study ▪ Preparing for 3rd / final consult with PMDA for PMDA trial with potential to lead to conditional approval / reimburseme
Slide 46: Contact
1 TSXV: RP OTCPK: REPCF www.replicel.com FRA:P6P2 CONTACT: R. Lee Buckler President & CEO 604.248.8693 lee@replicel.com VISIT US ON SOCIAL MEDIA
RepliCel Life Sciences — Investor Presentation (2021) on 6ix